Exelixis, Inc. (EXEL) Stock Analysis and Metrics

Exelixis

NASDAQ: EXEL

$55.34 ▼ -0.31 (-0.56%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap14.34 Bn

P/E17.20

P/S6.04

Div. Yield0.00

Revenue Growth (1y) (Qtr)9.97

Add ratio to table…

About

Exelixis, Inc. is an oncology company focused on discovering, developing, and commercializing next-generation medicines for the treatment of cancer. The company's core business involves advancing small molecule and biotherapeutic candidates through preclinical and clinical development, with an emphasis on tyrosine kinase inhibitors and antibody-drug conjugates. Exelixis generates revenue primarily from the sale of its marketed products and royalties earned through collaboration agreements.

Revenue is generated mainly through net product sales of CABOMETYX® and COMETRIQ®, which account for the majority of the company's income. Additional revenue comes from royalties on net sales of cabozantinib products outside the United States, earned under collaboration agreements with Ipsen and Takeda. The company serves healthcare providers, patients, and healthcare systems globally, with a focus on oncologists and specialty treatment centers.

The company operates through the following segments: Oncology Therapeutics and Collaborative Development.

• Oncology Therapeutics: This segment encompasses the discovery, development, and commercialization of Exelixis' proprietary oncology products, including small molecules and biotherapeutics. Key marketed products include CABOMETYX® (cabozantinib) tablets and COMETRIQ® (cabozantinib) capsules for various cancer indications. The segment also includes pipeline candidates such as zanzalintinib, XL309, XB010, XB628, and XB371, each targeting specific kinases or biological pathways in solid tumors.

• Collaborative Development: This segment involves strategic partnerships with third-party companies to advance the development and commercialization of Exelixis' product candidates. Collaborations include agreements with Ipsen and Takeda for the global commercialization of cabozantinib outside the U. S. and Japan, respectively. Additional partnerships exist with Roche, BMS, Merck, Catalent, Invenra, Adagene, Sairopa, and Insilico for the co-development of antibody-drug conjugates, bispecific antibodies, and small molecule inhibitors.

Exelixis holds a strong position in the oncology therapeutics market, particularly as a leader in tyrosine kinase inhibitor development for renal cell carcinoma and other hard-to-treat cancers. The company competes with major pharmaceutical firms such as Bristol-Myers Squibb, Merck & Co., Eisai, and Novartis, but differentiates itself through its focused pipeline, clinical trial data, and strategic collaborations that enhance its development capabilities and market reach.

Exelixis serves patients, healthcare providers, hospitals, and specialty oncology clinics worldwide. Specific customer names are not disclosed in the filing, but the company's products are distributed through wholesale and specialty pharmacy channels to end-users treating advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, pancreatic and extra-pancreatic neuroendocrine tumors, and medullary thyroid cancer.

Investment Thesis

▲ Bull case

Exelixis is strategically positioned to capture significant value from the ZANZA franchise, particularly through its colorectal cancer opportunity, which remains underappreciated by the market despite robust clinical and regulatory progress. The STELLAR-303 trial demonstrated a statistically significant 20% reduction in the risk of death in the intention-to-treat population for ZANZA plus atezolizumab versus regorafenib in previously treated metastatic colorectal cancer, with consistent OS benefit across key subgroups including RAS status and liver involvement. The FDA has accepted the NDA with a PDUFA date of December 3, 2026, and the company is on track for topline results on the dual primary endpoint of overall survival in patients without liver metastases by mid-2026, which could further strengthen the label and support broader adoption. This represents a $1.5 billion market opportunity in the U.S. third-line-plus CRC setting alone, with Exelixis having already expanded its GI sales team to accelerate CABOMETYX NET growth and prepare for ZANZA launch, indicating operational readiness beyond what is reflected in current guidance. Furthermore, the STELLAR-316 trial targeting MRD-positive stage II/III CRC patients post-definitive therapy addresses a high unmet need with poor prognosis (6-8 month median disease-free survival) and no approved systemic therapies, creating a potential franchise-defining opportunity that could extend ZANZA’s impact into earlier lines of therapy and significantly expand its addressable patient population beyond the current NDA scope.
Beyond colorectal cancer, Exelixis is building a diversified ZANZA franchise across multiple tumor types with de-risked catalysts that could drive multi-year growth, yet the market appears to be valuing the company primarily on near-term cabo performance. The company has seven ongoing or soon-to-start pivotal trials for ZANZA, including STELLAR-304 in non-clear cell RCC (expected H2 2026 readout), STELLAR-311 in neuroendocrine tumors (ahead of enrollment projections), and STELLAR-201 in recurrent meningioma (Phase II, high unmet need, no approved systemic therapies). Additionally, the LIGHTSPARK-033 and LIGHTSPARK-034 trials with Merck evaluate ZANZA plus belzutifan in distinct RCC settings, offering orthogonal MOA combinations that could overcome prior triplet therapy failures like LIGHTSPARK-12. The management team explicitly framed these as "multiple shots on goal" to establish ZANZA as the TKI of choice in RCC by the 2030s, leveraging cabo’s franchise-building playbook. Crucially, Exelixis’ R&D strategy is focused on high-value opportunities with disciplined investment, and the early pipeline (XL309, XB010, XB628, XB371) is progressing well, with XB628 noted as a novel bispecific with multiple IO arms that could be a very interesting combination in RCC if successful—representing an internal innovation engine that could sustain long-term franchise value beyond ZANZA.
Exelixis’ financial strength and capital allocation strategy provide a significant cushion and upside optionality that the market is underestimating, particularly given its aggressive share repurchase program and strong free cash flow generation. The company ended Q1 2026 with $1.4 billion in cash and marketable securities, repurchased $430.8 million of stock during the quarter (10 million shares at $42.99 avg), and has $159.4 million remaining under the $750 million October 2025 SRP, which it expects to complete this month. Additionally, the Board authorized a new $750 million SRP in May 2026 expiring Dec 2027, signaling confidence in intrinsic value and commitment to returning capital despite ongoing R&D investment. This financial flexibility allows Exelixis to sustain its R&D spend ($875M–$925M FY26 guidance) and pursue BD opportunities without compromising shareholder returns, while the Cabo franchise continues to grow—U.S. net product revenues up 8% YoY to $555M, global franchise up 12.5% to $764M, with TRx volume growing 14% vs. market basket’s 7%. The company is not only maintaining but accelerating its commercial execution in NET, having expedited GI sales team expansion to drive community penetration, and CABOMETYX remains the market leader in oral second-line-plus NET and #1 prescribed TKI in RCC. This combination of durable cash flow, disciplined capital allocation, and franchise-building execution creates a resilient foundation for long-term value creation that is not fully reflected in the current valuation.

Exelixis is strategically positioned to capture significant value from the ZANZA franchise, particularly through its colorectal cancer opportunity, which remains underappreciated by the market despite robust clinical and regulatory progress. The STELLAR-303 trial demonstrated a statistically significant 20% reduction in the risk of death in the intention-to-treat population for ZANZA plus atezolizumab versus regorafenib in previously treated metastatic colorectal cancer, with consistent OS benefit across key subgroups including RAS status and liver involvement. The FDA has accepted the NDA with a PDUFA date of December 3, 2026, and the company is on track for topline results on the dual primary endpoint of overall survival in patients without liver metastases by mid-2026, which could further strengthen the label and support broader adoption. This represents a $1.5 billion market opportunity in the U.S. third-line-plus CRC setting alone, with Exelixis having already expanded its GI sales team to accelerate CABOMETYX NET growth and prepare for ZANZA launch, indicating operational readiness beyond what is reflected in current guidance. Furthermore, the STELLAR-316 trial targeting MRD-positive stage II/III CRC patients post-definitive therapy addresses a high unmet need with poor prognosis (6-8 month median disease-free survival) and no approved systemic therapies, creating a potential franchise-defining opportunity that could extend ZANZA’s impact into earlier lines of therapy and significantly expand its addressable patient population beyond the current NDA scope.
Beyond colorectal cancer, Exelixis is building a diversified ZANZA franchise across multiple tumor types with de-risked catalysts that could drive multi-year growth, yet the market appears to be valuing the company primarily on near-term cabo performance. The company has seven ongoing or soon-to-start pivotal trials for ZANZA, including STELLAR-304 in non-clear cell RCC (expected H2 2026 readout), STELLAR-311 in neuroendocrine tumors (ahead of enrollment projections), and STELLAR-201 in recurrent meningioma (Phase II, high unmet need, no approved systemic therapies). Additionally, the LIGHTSPARK-033 and LIGHTSPARK-034 trials with Merck evaluate ZANZA plus belzutifan in distinct RCC settings, offering orthogonal MOA combinations that could overcome prior triplet therapy failures like LIGHTSPARK-12. The management team explicitly framed these as "multiple shots on goal" to establish ZANZA as the TKI of choice in RCC by the 2030s, leveraging cabo’s franchise-building playbook. Crucially, Exelixis’ R&D strategy is focused on high-value opportunities with disciplined investment, and the early pipeline (XL309, XB010, XB628, XB371) is progressing well, with XB628 noted as a novel bispecific with multiple IO arms that could be a very interesting combination in RCC if successful—representing an internal innovation engine that could sustain long-term franchise value beyond ZANZA.
Exelixis’ financial strength and capital allocation strategy provide a significant cushion and upside optionality that the market is underestimating, particularly given its aggressive share repurchase program and strong free cash flow generation. The company ended Q1 2026 with $1.4 billion in cash and marketable securities, repurchased $430.8 million of stock during the quarter (10 million shares at $42.99 avg), and has $159.4 million remaining under the $750 million October 2025 SRP, which it expects to complete this month. Additionally, the Board authorized a new $750 million SRP in May 2026 expiring Dec 2027, signaling confidence in intrinsic value and commitment to returning capital despite ongoing R&D investment. This financial flexibility allows Exelixis to sustain its R&D spend ($875M–$925M FY26 guidance) and pursue BD opportunities without compromising shareholder returns, while the Cabo franchise continues to grow—U.S. net product revenues up 8% YoY to $555M, global franchise up 12.5% to $764M, with TRx volume growing 14% vs. market basket’s 7%. The company is not only maintaining but accelerating its commercial execution in NET, having expedited GI sales team expansion to drive community penetration, and CABOMETYX remains the market leader in oral second-line-plus NET and #1 prescribed TKI in RCC. This combination of durable cash flow, disciplined capital allocation, and franchise-building execution creates a resilient foundation for long-term value creation that is not fully reflected in the current valuation.

▼ Bear case

Exelixis faces significant near-term execution risk in its colorectal cancer launch plans for ZANZA, despite optimistic timelines, as the STELLAR-303 trial’s dual primary endpoint design introduces regulatory uncertainty that could delay or limit label approval. While the trial met one dual primary endpoint (OS in ITT population with 20% risk reduction), the other endpoint (OS in NLM population) showed only a trend at data cutoff and remains immature, with topline results expected mid-2026 depending on event rates. The FDA may require full approval of both endpoints for broad labeling, or could approve with restrictions (e.g., only for NLM patients or with confirmatory trial requirements), which would materially limit the addressable patient population and commercial potential. Furthermore, the company’s reliance on atezolizumab as a fixed combination partner introduces dependency on Roche’s supply, pricing, and competitive positioning in the CRC landscape, where atezolizumab has not demonstrated strong standalone activity in later-line CRC and faces intense competition from pembrolizumab and nivolumab-based regimens. This regulatory and partnership complexity could delay meaningful revenue contribution from ZANZA beyond current expectations, leaving Exelixis overly dependent on the cabo franchise for near-term growth.
The Cabo franchise, while currently growing, is experiencing increasing margin pressure and competitive headwinds that are not being adequately addressed in management commentary, particularly regarding gross-to-net deterioration and evolving market dynamics. Gross-to-net for the cabo franchise rose to 30.2% in Q1 2026, up from prior periods, driven by higher 340B volume, Medicare Part D discounts/rebates, and copay assistance—trends that are likely to persist or worsen as payer scrutiny intensifies and inflation reduction act provisions take full effect. This directly impacts net realized prices and could erode the profitability of cabo’s volume growth, especially as Exelixis expands its GI sales team to chase NET share, potentially increasing promotional and discounting expenses in a crowded market. Meanwhile, the company’s own data shows CABOMETYX TRx volume grew 14% YoY in Q1 2026 vs. market basket’s 7%, but this outperformance may not be sustainable given the maturity of the RCC and NET markets, where cabo is already the #1 prescribed TKI and #1 oral agent in second-line-plus NET. With limited room for further share gains in these established segments and no near-term label expansions for cabo, growth will increasingly depend on pricing power or volume in commoditizing markets—both of which are under threat from generic competition and payer pressure, yet management highlighted only top-line growth without addressing net pricing sustainability or long-term margin resilience.
Exelixis’ ambitious pipeline strategy for ZANZA carries substantial clinical and commercial risk that is being downplayed, particularly in light of recent failures in RCC combination therapies that suggest the market may be overestimating the ease of establishing new standards of care. The LIGHTSPARK-12 triplet failure (pembro/lenva plus belzutifan) was explicitly cited by management as reinforcing that triplet therapy in clear cell RCC is "not an easy game," yet the company is pursuing multiple doublet combinations (e.g., ZANZA plus belzutifan in LIGHTSPARK-033/034) without acknowledging that belzutifan monotherapy has limited efficacy as a single agent and that VEGF/TKI combinations have historically struggled to show OS benefit in RCC despite PFS signals. Furthermore, the STELLAR-304 trial in non-clear cell RCC targets a heterogeneous population (approximately 25% of RCC cases) with no prior Phase 3 positive readout, and success may be histology-specific, making broad label approval uncertain. The management team’s framing of "multiple shots on goal" and long-term 2030s franchise vision does not adequately address the high failure rate in oncology drug development or the capital intensity of pursuing seven pivotal trials simultaneously, which could strain R&D productivity if multiple readouts are negative. Combined with the fact that ZANZA remains unapproved for any use and is subject to typical clinical trial risks (safety, efficacy, enrollment delays), the pipeline could deliver far less value than implied by the current strategic narrative, leaving Exelixis vulnerable if cabo growth decelerates before ZANZA achieves meaningful commercial traction.

Exelixis faces significant near-term execution risk in its colorectal cancer launch plans for ZANZA, despite optimistic timelines, as the STELLAR-303 trial’s dual primary endpoint design introduces regulatory uncertainty that could delay or limit label approval. While the trial met one dual primary endpoint (OS in ITT population with 20% risk reduction), the other endpoint (OS in NLM population) showed only a trend at data cutoff and remains immature, with topline results expected mid-2026 depending on event rates. The FDA may require full approval of both endpoints for broad labeling, or could approve with restrictions (e.g., only for NLM patients or with confirmatory trial requirements), which would materially limit the addressable patient population and commercial potential. Furthermore, the company’s reliance on atezolizumab as a fixed combination partner introduces dependency on Roche’s supply, pricing, and competitive positioning in the CRC landscape, where atezolizumab has not demonstrated strong standalone activity in later-line CRC and faces intense competition from pembrolizumab and nivolumab-based regimens. This regulatory and partnership complexity could delay meaningful revenue contribution from ZANZA beyond current expectations, leaving Exelixis overly dependent on the cabo franchise for near-term growth.
The Cabo franchise, while currently growing, is experiencing increasing margin pressure and competitive headwinds that are not being adequately addressed in management commentary, particularly regarding gross-to-net deterioration and evolving market dynamics. Gross-to-net for the cabo franchise rose to 30.2% in Q1 2026, up from prior periods, driven by higher 340B volume, Medicare Part D discounts/rebates, and copay assistance—trends that are likely to persist or worsen as payer scrutiny intensifies and inflation reduction act provisions take full effect. This directly impacts net realized prices and could erode the profitability of cabo’s volume growth, especially as Exelixis expands its GI sales team to chase NET share, potentially increasing promotional and discounting expenses in a crowded market. Meanwhile, the company’s own data shows CABOMETYX TRx volume grew 14% YoY in Q1 2026 vs. market basket’s 7%, but this outperformance may not be sustainable given the maturity of the RCC and NET markets, where cabo is already the #1 prescribed TKI and #1 oral agent in second-line-plus NET. With limited room for further share gains in these established segments and no near-term label expansions for cabo, growth will increasingly depend on pricing power or volume in commoditizing markets—both of which are under threat from generic competition and payer pressure, yet management highlighted only top-line growth without addressing net pricing sustainability or long-term margin resilience.
Exelixis’ ambitious pipeline strategy for ZANZA carries substantial clinical and commercial risk that is being downplayed, particularly in light of recent failures in RCC combination therapies that suggest the market may be overestimating the ease of establishing new standards of care. The LIGHTSPARK-12 triplet failure (pembro/lenva plus belzutifan) was explicitly cited by management as reinforcing that triplet therapy in clear cell RCC is "not an easy game," yet the company is pursuing multiple doublet combinations (e.g., ZANZA plus belzutifan in LIGHTSPARK-033/034) without acknowledging that belzutifan monotherapy has limited efficacy as a single agent and that VEGF/TKI combinations have historically struggled to show OS benefit in RCC despite PFS signals. Furthermore, the STELLAR-304 trial in non-clear cell RCC targets a heterogeneous population (approximately 25% of RCC cases) with no prior Phase 3 positive readout, and success may be histology-specific, making broad label approval uncertain. The management team’s framing of "multiple shots on goal" and long-term 2030s franchise vision does not adequately address the high failure rate in oncology drug development or the capital intensity of pursuing seven pivotal trials simultaneously, which could strain R&D productivity if multiple readouts are negative. Combined with the fact that ZANZA remains unapproved for any use and is subject to typical clinical trial risks (safety, efficacy, enrollment delays), the pipeline could deliver far less value than implied by the current strategic narrative, leaving Exelixis vulnerable if cabo growth decelerates before ZANZA achieves meaningful commercial traction.

Geographical Breakdown of Revenue (2026)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2026)

Geographical Breakdown of Revenue (2026)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2026)

Geographical Breakdown of Revenue (2026)

Peer Comparison

Create an account

Sign In

Reset Password